Due to the evidence that HDAC6 inhibition improves cognitive dysfunction in neurodegenerative models, attenuates neuroinflammation, and enhances tumor control, HDAC6 inhibitors may be an ideal candidate for pharmaceutical intervention of CICD. Here, HDAC6 is linked to neoplasm.